News: UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

64.54EUR
22 May 2015
Change (% chg)

€2.00 (+3.20%)
Prev Close
€62.54
Open
€62.36
Day's High
€65.24
Day's Low
€62.00
Volume
517,712
Avg. Vol
348,165
52-wk High
€75.62
52-wk Low
€56.59

Search Stocks
Select another date:

Thu, Apr 30 2015

Belgium's UCB posts double-digit sales increase in first quarter

BRUSSELS, April 30 - Belgian pharmaceutical group UCB reported double-digit growth in sales for the first quarter on Thursday, benefiting from a strong increase in its new products and even an uptick in orders for its off-patent drug Keppra.

India's Dr Reddy's to buy some UCB brands for $128 million

MUMBAI - India's second-largest drugmaker by sales, Dr Reddy's Laboratories Ltd , will buy some established brands of Belgian drugmaker UCB SA in South Asia for 8 billion rupees ($128.38 million), the company said on Wednesday.

UPDATE 1-India's Dr Reddy's to buy some UCB brands for $128 mln

* Acquired business had FY 2014 sales of about 1.5 bln rupees

India's Dr Reddy's to buy select brands from UCB for $128 mln

MUMBAI, April 1 - Dr Reddy's Laboratories Ltd , India's second-largest drugmaker by sales, said it will buy some established brands of Belgian drugmaker UCB SA in India, Nepal, Sri Lanka and Maldives for 8 billion rupees ($128.38 million).

BRIEF-UCB to sell its established brands portfolio in India to Dr. Reddy's

* To sell its established brands portfolio in India to Dr. Reddy's for 118 million euros ($126.96 million)

BRIEF-FSMA suspends trading of UCB till 9.30 am

* Restoration expected at 01/04/2015 at 09:30 am Further company coverage:

BRIEF-UCB completes institutional Eurobond offering

* Has completed offering of 350 million euros ($382.13 million) senior unsecured bonds, due April 2022, to be issued under its 3 billion euro EMTN programme

Dr.Reddy's in talks to buy UCB India business for $135 mln - source

MUMBAI, March 10 - Indian drugmaker Dr.Reddy's Laboratories Ltd is in talks to acquire the Indian operations of Belgian pharmaceutical company UCB SA for about $135 million, said a person with direct knowledge of the matter.

UCB sees three newer drugs driving 2015 income increase

BRUSSELS - Belgian pharmaceutical company UCB forecast improved income in 2015 on Friday based on continued growth of its three newer drugs, although its profit outlook is not as bullish as that of the market.

UCB sees three newer drugs driving 2015 income increase

BRUSSELS, Feb 27 - Belgian pharmaceutical company UCB forecast improved income in 2015 on Friday based on continued growth of its three newer drugs, although its profit outlook is not as bullish as that of the market.

Select another date:
Search Stocks